A COMPREHENSIVE APPROACH TO TREATING BENIGN BREAST DISEASES IN OVERWEIGHT PATIENTS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

A significant increase in the incidence of benign breast diseases in women is an important medical and social problem. Overweight is a leading risk factor for this pathology. Currently, there is no individual approach to managing overweight women at high risk for mammary dysplastic changes. Objective: to substantiate the efficiency of a comprehensive approach to treating fibrocystic breast disease in overweight patients. Subjects and methods. The investigation enrolled 164 overweight women with fibrocystic breast disease. The treatment was aimed to lose weight in the use of Indinol Forto. Results. Over a 6-month period, it was possible to normalize quality of life indicators, to reduce weight, and to achieve positive changes, as evidenced by control ultrasound. Conclusion. The comprehensive approach to treating overweight patients with benign breast diseases can yield positive results.

Full Text

Restricted Access

About the authors

A. M Plashchinskaya

City Hospital Eight

Email: plashchinskaya_anna@mail.ru
Obstetrician/Gynecologist 19, Krasnoarmeiskaya St., Rostov-on-Don, Rostov Region 344010, Russia

A. F Mikhelson

Rostov State Medical University, Ministry of Health of the Russian Federation

Email: michelson.a.f@mail.ru
MD; Head, Obstetrics and Gynecology Department Three, Faculty for Advanced Training and Professional Retraining of Specialists 29, Nakhichevanskiy Lane, Rostov-on-Don, Rostov Region 344022, Russia

E. Yu Lebedenko

Rostov State Medical University, Ministry of Health of the Russian Federation

Email: lebedenko08@mail.ru
MD; Professor, Obstetrics and Gynecology Department Three, Faculty for Advanced Training and Professional Retraining of Specialists 29, Nakhichevanskiy Lane, Rostov-on-Don, Rostov Region 344022, Russia

N. V Ermolova

Rostov State Medical University, Ministry of Health of the Russian Federation

Email: rniiap.ermolova@gmail.com
MD; Associate Professor; Head, Department of Obstetrics and Gynecology, Research Institute of Obstetrics and Pediatrics 43, Mechnikov St., Rostov-on-Don, Rostov Region 344012, Russia

References

  1. Беспалов В.Г., Травина М.Л. Фиброзно-кистозная болезнь и риск рака молочной железы (обзор литературы). Опухоли женской репродуктивной системы. 2015; 4: 58-70.
  2. Корженкова Г.П. Фиброзно-кистозная мастопатия: вариант нормы или болезнь? Онкогинекология. 2012; 3: 46-55.
  3. Ласачко С.А. Современные представления о дисгормональных заболеваниях молочных желез. Новообразование. 2017; 1(16): 29-35.
  4. Сметник А.А., Сметник В.П., Киселев В.И. Опыт применения индол-3-карбинола в лечении заболеваний молочной железы и профилактике рака молочной железы. Акушерство и гинекология. 2017; 2: 106-12.
  5. Радзинский В.Е. Медицина молочной железы и гинекологические заболевания. М.: StatusPraesens; 2017. 335 с.
  6. Солодко В.А., Рожкова Н.И. Диффузные доброкачественные заболевания молочных желез. Диагностика и лечение. М.: Спец. изд-во медицинской книги; 2012. 117 с.
  7. Серов В.Н., Тагиева Т.Т. Доброкачественные заболевания молочных желез. Гинекологическая эндокринология. М.: МЕДпресс-информ; 2015. 370 с.
  8. Высоцкая И.В., Летягин В.П., Черенков В.Г., Лактионов К.П., Бубликов И.Д. Клинические рекомендации Российского общества онкомаммологов по профилактике рака молочной железы, дифференциальной диагностике, лечению предопухолевых и доброкачественных заболеваний молочных желез. Опухоли женской репродуктивной системы. 2016; 12(3): 43-52.
  9. Samali E., Trichopoulos D., Lagiou A., et al. The hormonal profile of benign breast disease. Br. J. Cancer. 2013; 108 (1): 199-204.
  10. Von Karsa L. Development and implementation of guidelines for quality assurance in breast cancer screening: The European experience. Salud. PublicaMex. 2013; 55(3): 318-28.
  11. Zavoloka A.V. Benign breast tumors diagnostic recent advances. J. Health. Sci. 2013; 3(10): 665-74.
  12. Marconett C.N. et al. Indole-3-carbinol disrupts estrogen receptor-alpha dependent expression of insulin-like growth factor-1 receptor and insulin receptor substrate-1 and proliferation of human brest cancer cells. Mol. Cell. Endocrinol. 2012; 363 (1-2): 74-84.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies